To evaluate the neurovascular structure-adjacent frozensection examination (NeuroSAFE) technique in a British setting in men undergoing robot-assisted laparoscopic radical prostatectomy (RALP) .
Patients and Methods
We retrospectively analysed our prospectively maintained database of patients who underwent RALP between November 2008 and February 2017. We examined preoperative pathological and functional parameters, intraoperative nerve sparing (NS), postoperative histology, as well as functional and oncological follow-up. We compared those who had a NeuroSAFE approach and those who had NS without NeuroSAFE. We also compared all the RALPs before and after the introduction of NeuroSAFE. Statistical analysis was done using the two-tailed t-test and chi-squared analysis.
Results
This single surgeon series included 417 RALPs, including 120 NeuroSAFEs. The NeuroSAFE cohort had a greater proportion of D'Amico high-risk disease (30.8% vs 9.6%, P < 0.001), higher Gleason scores and higher pT stage compared to the non-NeuroSAFE NS cohort. After the introduction of NeuroSAFE, more preoperatively potent men underwent bilateral NS with pT2 disease (84.6% vs 66.3%, P = 0.002) and more overall NS were performed in patients with pT3 disease (65.1% vs 36.7%, P = 0.012). Overall positive surgical margin (PSM) rates were lower in the NeuroSAFE cohort compared to those who had NS without NeuroSAFE (9.2% vs 17.8%, P = 0.04). The 12-month potency rates were also higher in the NeuroSAFE cohort for both bilateral (77.3% vs 50.9%, P = 0.009) and unilateral (70.6% vs 40%, P = 0.04) NS. Pad-free continence was also higher in the NeuroSAFE group (85.7% vs 70.9%, P = 0.019), but there was no significant difference between those who were wearing ≤1 safety pad. Although we only had short-term oncological follow-up, it did not significantly differ between the two groups.
Introduction
Since the first description of the nerve sparing (NS) technique in open radical prostatectomy (RP) by Walsh et al. [1] in 1982, there has been significant progress in the understanding of the neurovascular anatomy of the prostate. Contemporary knowledge of the prostatic neurovascular anatomy has been driven primarily by high-quality cadaveric studies and the increasing application of robot-assisted laparoscopic RP (RALP) with better magnification and three-dimensional visualisation [2] [3] [4] [5] . Better knowledge of prostatic neuroanatomy will undoubtedly improve NS techniques with a consequent positive impact on erectile function and potentially continence recovery [6] . However, despite improved anatomical understanding and technological advancement of the robotic platform, NS has often been compromised in an attempt to ensure a negative surgical margin. The main barrier to clinicians offering an aggressive NS approach is the lack of a convincing strategy that can ensure oncological safety. The diagnostic accuracy of current imaging methods in predicting neurovascular cancer involvement is poor. Hence, clinicians rely on parameters such as preoperative erectile function status, Gleason score, Clinical and radiological T-stage, location, and volume of the tumour focus, to be advised on whether offering NS is safe. Intraoperative frozen-section analysis of the excised prostate specimen during a RP has the potential to address the aforementioned issues associated with NS during a RP. The Martini-Klinik in Hamburg, Germany developed the intraoperative neurovascular structure-adjacent frozen-section examination (NeuroSAFE) technique, which has since been internally validated by their group [7, 8] . Schlomm et al. [8] reported the Martini clinic experience with 11 069 cases of open RP and RALP performed with NeuroSAFE. They reported an increase in NS from 81% to 97% across all stages. Their overall positive surgical margin (PSM) rates decreased from 22% to 15% across all stages. Beyer et al. [7] from the same group subsequently reported on a cohort of 1 178 patients who underwent NeuroSAFE with a RALP. Similar to their previous series they reported an increase in NS from 81% to 97% across all stages. Their overall PSM rates decreased from 24% to 16% across all stages. Hertfordshire and South Bedfordshire Urological Cancer Centre at the Lister Hospital, Stevenage, UK adopted the NeuroSAFE technique in November 2012. In the present study, we aimed to appraise the NeuroSAFE technique in a British setting in men undergoing a RALP.
Patients and Methods

Study Population and Data Source
The study was registered with Hertfordshire Audit Registration Team. We retrospectively reviewed the demographic and clinical data recorded in a prospectively maintained database at the Lister Hospital, Stevenage, UK, for patients who underwent a RALP from November 2008 to February 2017. In all, 965 men underwent a RALP in the study period (including 217 NeuroSAFEs). The NeuroSAFE programme was initiated in November 2012. The procedure has been adopted by three surgeons (J.A., N.V. and T.M.L.); however, data for only one (J.A.) were included in the final analysis. This is because he pioneered this technique at our institution and hence was the only one who had >12 months functional and oncological follow-up for both NeuroSAFE and non-NeuroSAFE NS patients. The frozen-section analysis was performed by two uro-pathologists (S.A., A.N.). The following parameters were recorded in the database: patient age, presentation PSA level, detailed preoperative biopsy pathology (Gleason score, number of cores, percentage of tumour involved, cT stage), overall and robotic console operating time, estimated blood loss, complications graded by the Clavien-Dindo system, RP specimen pathology (Gleason score, margin status, TNM stage, and specimen weight), postoperative PSA levels, adjuvant/salvage treatment, as well as continence and erectile function.
Definition of Outcomes
For the NeuroSAFE cohort, if a frozen section was positive and the ipsilateral neurovascular bundle (NVB) was removed (i.e. converted to wide excision on that side), it was orientated to its apical, basal, medial and lateral surfaces. If there was a T2 PSM on frozen section and no cancer found in the NVB, the overall radial surgical margin was deemed negative (i.e. PSM on frozen section was presumed artefactual). If tumour was found in the NVB outside the prostate capsule but not at the lateral surface of the excised NVB, the final histology was defined as pT3 but with a negative overall margin. A PSM was reported if on the ultimate histological analysis tumour was present at the inked margin outside the previously analysed/painted area of the frozen section (e.g. apex, base, posterior, anterior or through the NVB) or in the rare event of a false-negative frozen section. Patients were defined as continent if they used no pads or one precautionary pad, similar to other quality-of-life studies [9] . Patients were defined as potent if they had a satisfactory erection for penetrative intercourse with or without a phosphodiesterase type 5 (PDE-5) inhibitor. Both continence and potency were derived from follow-up consultations recorded by the surgeon and were included in the analysis if follow-up was ≥12 months. Adjuvant treatment was defined as that which was initiated before a PSA threshold of 0.2 ng/mL was reached. Biochemical recurrence (BCR) was defined as a PSA level of >0.2 ng/mL after RALP and treatment received after this was defined as salvage. Eligible patients were recruited for the Radiotherapy and Androgen Deprivation In Combination after Local Surgery (RADICALS) trial.
RALP Technique and Intraoperative FrozenSection Protocol
We have previously published our technique for RALP and intraoperative frozen-section analysis [10] . During the procedure, the patients underwent a unilateral or bilateral NS dissection. Once the prostate was completely disconnected it was removed intraoperatively through the midline port (only the camera arm was undocked) as shown in Fig. 1 .
The specimen was then painted on the surface (red = right, violet = left) of where the NVBs were dissected and sprayed with 'ink aid' as shown in Fig. 2 . The lateral (painted) aspects of the specimen were serially sectioned with a cryostat in the histology laboratory and examined for the presence and location of tumour, and proximity to the inked margin. During the time that the specimen was undergoing frozensection analysis, the urethrovesical anastomosis and, if indicated, pelvic lymph node dissection were performed.
The presence of even a single neoplastic gland extending to the margin was called positive and the ipsilateral nerve bundle was excised before completion of the procedure. All tissue from the cut edge of Denonvilliers' fascia medially, the pararectal fat laterally, the pedicle cranially, and just beyond the urethrovesical anastomosis (including the puboprostatic ligament and Walsh's pillar) caudally was removed en bloc. All specimens were further assessed in a paraffin-wax block routinely to confirm the final histopathology.
Patient Selection
All patients with low and intermediate D'Amico classification were offered a RALP. Patients with high-risk disease were offered RALP only if their clinical and radiological stage was ≤T3a. As the series matured and our confidence in the NeuroSAFE technique increased, we offered more young, preoperatively potent men with T3a disease on MRI, a bilateral interfascial NS RALP with NeuroSAFE. However, most were still encouraged to have a unilateral NS or wide local excision. Patients with a preoperative clinical or radiological stage T3b disease were not offered a RALP at the time of this study.
Outcomes Measures
Proportion of potent patients being offered NS RALP
(before vs after introduction of NeuroSAFE) 2 PSM rates (NeuroSAFE vs NS without NeuroSAFE) 3 Oncological follow-up including BCR and adjuvant/salvage treatment (NeuroSAFE vs NS without NeuroSAFE) 4 12-month erectile function and continence rates (NeuroSAFE vs NS without NeuroSAFE) 
Statistical Analysis
The proportions were compared using the two-tailed t-test for continuous variables and chi-squared test for categorical variables. A P < 0.05 was considered statistically significant.
Results
Demographics and Baseline Characteristics
This single surgeon series included 417 RALPs, including 164 before NeuroSAFE introduction and 253 after; including 120 NeuroSAFE RALPs and 157 NS RALPs without NeuroSAFE (50 of these were performed after NeuroSAFE was introduced; Table 1 ). The NeuroSAFE cohort was more contemporary overall with a median (range) year of surgery of 2015 (2012-2017) compared to 2011 (2008-2016) of the non-NeuroSAFE NS cohort (P < 0.001). The mean (range) follow-up of the study was 39 (1-99) months. The median age of the NeuroSAFE and non-NeuroSAFE NS cohorts were 58 and 62 years, respectively (P = 0.003). There was no significant difference between the two cohorts for preoperative PSA level and cT-stage. The NeuroSAFE cohort had a significantly higher proportion of high-grade (8.3% vs 2.5%, P = 0.03) and high-risk (30.8% vs 9.6%, P = 0.029) prostate cancer graded by D'Amico classification than the non-NeuroSAFE NS cohort. The non-NeuroSAFE NS cohort had a higher proportion of low-grade (55.4% vs 30.8%, P < 0.001) and low-risk (40.1% vs 17.5%, P < 0.001) prostate cancer than the NeuroSAFE group. On final histology, the NeuroSAFE cohort had less Gleason score 6 (25.8% vs 42%, P = 0.005), more Gleason score 4 + 3 = 7 or higher (22.5% vs 8.9%, P = 0.002), and a higher proportion of T3 disease (23.3% vs 10.8%, P = 0.005) than their non-NeuroSAFE NS counterparts. There was no statistically significant difference between the groups in the proportion of patients who had bilateral or unilateral NS. However, three patients (2.5% vs 0%, P = 0.046) in the NeuroSAFE group had a wide excision due to either bilateral positive frozen section (one) or a positive frozen section in a unilateral NS (two).
Outcomes Measures
Proportion of Patients Being Offered NS RALP
Before the introduction of NeuroSAFE, 145 RALPs were done in potent men vs 193 after. Although the proportions of overall and bilateral NS were slightly higher after the introduction of NeuroSAFE (69% before vs 75.1% after for overall NS [P = 0.16] and 63% before vs 73.8% after for bilateral NS, [P = 0.07]), this was not statistically significant (Table 2 ).
However, when categorised by pT stage, there was a significantly higher proportion of men who had bilateral NS (66.3% vs 84.6%, P = 0.002) for pT2 disease and overall NS (36.7% vs 65.1%, P = 0.012) for pT3 disease, after the introduction of NeuroSAFE.
PSM Rates
The overall PSM rates for the NeuroSAFE and nonNeuroSAFE NS cohorts were 9.2% and 17.8%, respectively (P = 0.04; Table 3 ).
In pT2 disease, PSM rates for the NeuroSAFE and nonNeuroSAFE NS cohorts were 7.6% vs 15% (P = 0.09), respectively. In the NeuroSAFE cohort the areas of PSM were: base (two), apex (two) and circumferential (three). In the non-NeuroSAFE NS cohort the areas of PSM were: base (one), apex (14) and circumferential (six). In pT3 disease, the overall PSM rate for the NeuroSAFE and non-NeuroSAFE NS cohorts was 14.3% vs 41.2% (P = 0.042), respectively. In the NeuroSAFE cohort the areas of PSM were: base (two), apex (one) and circumferential (one). In the non-NeuroSAFE NS cohort the areas of PSM were: base (one), apex (two) and circumferential (four).
Oncological Follow-up
In both groups >90% of the patients had PSA follow-up available ( Table 3 ). The mean PSA follow-up was 15.6 months and 31.4 months (P < 0.001) in the NeuroSAFE and non-NeuroSAFE NS groups, respectively. BCR occurred in 1.7% and 1.9% of the NeuroSAFE and non-NeuroSAFE NS groups, respectively (P = 0.88). There was no statistically significant difference in the number of patients who received salvage or adjuvant radiotherapy, although there was a higher percentage in the NeuroSAFE group for adjuvant radiotherapy (5.8% vs 1.9%, P = 0.083).
The 12-month Functional Outcomes
The 12-month continence rates were available for 58.3% of the NeuroSAFE patients and 80.9% of the non-NeuroSAFE NS patients (P < 0.001; Table 4 ). Of these, 94.3% of the NeuroSAFE cohort and 91.3% of the non-NeuroSAFE NS cohort were continent (P = 0.46). There was a significant difference in the pad free rates (85.7% vs 70.9%, P = 0.019) in favour of the NeuroSAFE group.
In men who had good spontaneous erections before undergoing a bilateral NS RALP, the 12-month potency rates (erections sufficient for intercourse with or without PDE-5 inhibitors) were 77.3% and 50.9% (P = 0.007) in favour of the NeuroSAFE group. Moreover, a larger proportion of the NeuroSAFE cohort did not need PDE-5 inhibitors (47.7% vs 27.3%, P = 0.036).
In men who had good spontaneous erections before undergoing a unilateral NS RALP, the 12-month potency rates were 70.6% and 40% (P = 0.044) in favour of the NeuroSAFE group. There was no significant difference between those who did not need PDE-5 inhibitors (17.6% vs 10%, P = 0.48) for the NeuroSAFE and non-NeuroSAFE NS groups, respectively. Men who already had erectile dysfunction preoperatively had poor potency outcomes in all scenarios.
Concordance Rates Between Excised NVBs and Final Histology
In all, 227 NVBs were analysed in the NeuroSAFE group (107 bilateral and 13 unilateral frozen sections; Tables 5 and 6 ). When compared to the final paraffin-wax section, frozen section had a very high sensitivity, specificity, positive predictive value (PPV) and negative PV (NPV) as shown in Table 5 . A total of 33 (14.5%) NVBs were excised due to a positive result on the intraoperative frozen section. Of these, 14 (42.4%) had tumour identified on final histology. Given this, the diagnostic accuracy of our intraoperative frozen section is summarised in Table 6 .
Discussion
The present study emphasises that the NeuroSAFE technique facilitates safe aggressive NS. We have increased our confidence in performing more bilateral NS for patients, and are offering NS in a larger proportion of higher-risk disease. Furthermore, with this technique we have seen a trend towards reduced PSM rates across all stages and improved 12-months erectile function rates. The impact of PSMs on BCR rates and cancer-specific survival has been an area of contention. However, achieving a negative surgical margin is a surrogate marker for the quality of a RALP, which surgeons aspire to achieve. Stephenson et al. [11] reported in a series of 11 521 patients who underwent a RP that the 15-year cancer-specific survival was not significantly associated with surgical margin status after adjusting for covariates. PSMs were associated with increased BCR and need for salvage radiotherapy. In the present study, despite the higher proportion of D'Amico high-risk disease in the NeuroSAFE cohort, the overall PSM rates decreased significantly from 17.8% to 9.2% with the use of the NeuroSAFE approach. For T2 disease the PSM rates decreased from 15% to 7.6%, although this did not achieve statistical significance. However, for T3 disease there was a statistically and clinically significant decrease in PSM rates from 41.2% to 14.3%. These findings corroborate those of the Martini clinic [7, 8] . The marginally better numbers may relate to the fact that our present results are based on data from a single surgeon who was already experienced in both open RP and laparoscopic RP with and without NS prior to undertaking the robotic approach. Given this experience, we believe that our present reported outcomes are unlikely biased by the surgeon's learning curve. In addition, 50 of 153 (31.8%) analysed nonNeuroSAFE NS cases were done after the introduction of NeuroSAFE, due to the unavailability of the pathology service.
In our present study, short-term oncological follow-up data, in terms of BCR, was available for a high proportion of patients. With a mean follow-up of 15.6 months, the NeuroSAFE approach appears to be safe with a BCR rate of 1.7%. Both of these patients had negative surgical margins and high-risk disease. Moreover, both PSA relapses were within 3 months post-RALP, suggesting that it was more likely the aggressiveness of the disease, and not the technique, which was responsible. They both received salvage radiotherapy. The non-NeuroSAFE NS cohort had three BCRs, two of which had negative margins but aggressive disease and recurred 6 months postoperatively. The third relapse had a positive circumferential margin and recurred 24 months postoperatively. Although there was a higher proportion of patients in the NeuroSAFE cohort who underwent adjuvant radiotherapy (5.8% vs 1.9%) this difference was not statistically significant. Only three of the seven patients in this small group had a positive frozen *Continent = no pads or one precautionary 'safety' pad at ≥12 months of follow-up; † Potent = erections sufficient for intercourse with or without PDE-5 inhibitors at ≥12 months of follow-up. Table 5 Concordance between frozen-section and paraffin-wax sections.
Frozen section positive Frozen section negative
Paraffin positive 27* 3 Paraffin negative 5 191 section and two of these had tumour identified in the excised NVB. There was no apparent correlation between those who needed adjuvant treatment and whether they had a positive frozen section or tumour in the excised NVB. The need for adjuvant treatment was based on higher-risk disease pT3a/ pT3b, presence of a PSM on final histology, or progressively rising PSA level below the BCR threshold of 0.2 ng/mL. Additionally, as most of the NeuroSAFE cohort was more contemporary, there was an increasing trend to recommend adjuvant treatment with lower supersensitive PSA values based on more up-to-date evidence [12] [13] [14] .
The aggressiveness and extent (unilateral or bilateral) of the NS has been suggested to influence erectile function rates. Tewari et al. [15] in a retrospective series of 2 317 patients who underwent RALP, concluded that a greater degree of NS had higher rates of intercourse and return to baseline sexual function. In our present series, there was a significant improvement in 12-month potency rates in patients who underwent either bilateral or unilateral NS when comparing the NeuroSAFE patients with their non-NeuroSAFE NS counterparts. The potency rates in patients who underwent a bilateral NS were 77.3% and 50.9%, respectively (P = 0.007). The potency rates in patients who underwent a unilateral NS were 70.6% and 40%, respectively (P = 0.044). Furthermore, at ≥12 months of follow-up, 47.7% of the patients who had bilateral NS had erections satisfactory for penetrative intercourse spontaneously without PDE-5 inhibitors in the NeuroSAFE cohort compared to 27.3% of the nonNeuroSAFE NS cohort (P = 0.036). These results would be comparable with patients who had Grade 1-2 NS in the Tewari et al. [15] series, although their study does not specifically compare bilateral vs unilateral NS. Moreover, in their paper, Tewari et al. [15] used a risk stratification method based on preoperative PSA level, DRE, biopsy and MRI to decide on the grade of NS to perform, whereas in our present series the degree of NS was similar across the board. We contend that the addition of NeuroSAFE to the arsenal of tools in enhancing NS RALP enables the surgeon to offer a more robust NS uninhibited by the aggressiveness of the disease, without compromising margin status, because of the safety net of the frozen section. We believe that without the benefit of NeuroSAFE, the incremental approach compromised the quality of the NS too much in our hands.
In our present analysis, we have shown that we get better potency and margin rates despite removing 14.5% of our NVBs, than if we do incremental NS.
Unilateral NS in the NeuroSAFE cohort included those in whom a unilateral frozen section was performed (i.e. contralateral wide excision due to high volume, extensive or cT3 disease, 11 patients), as well as those who had a bilateral NS with one NVB excised due to a positive frozen-section result (26 patients). In our present series, we found the unilateral NS potency rates in the NeuroSAFE cohort to be quite high and actually approached those of bilateral NS. The authors believe that it is thus better to have one aggressively spared nerve than two incrementally or incompletely spared ones. Conversely, there was a small risk (2.5%) of having bilateral wide excision with NeuroSAFE if both sides were positive on the frozen section of a bilateral NS or the unilateral frozen section was positive.
We confirmed the reliability of our frozen-section analysis with its high concordance with the paraffin-wax sections.
With a negative result on the frozen section, the operating surgeon can be confident about the margin status of the NS with a negative predictive value of 98.5%. Of the excised NVBs, 42.4% contained tumour, which correlates well with other publications [8, 16] . From an oncological point of view, it is therefore necessary to do so in every case. However, optimising oncological safety can be done confidently without losing much in the way of functional outcomes, given our unilateral NS potency rates.
Currently in the UK the uptake of the NeuroSAFE approach is not widespread. Our group published our initial experience which remains UK's first and only published series of the NeuroSAFE technique [10] . Potential factors that may pose as impediments to its uptake include perceived high costs and lack of surgical/pathological expertise. There is a likely learning curve to achieving both surgical and pathological expertise. Although not formally evaluated, the authors do not envisage the learning curves to be long under appropriate mentorship, for a trained RALP surgeon and uro-pathologist. Furthermore, Beyer et al. [7] reported significantly low PSM rates with the NeuroSAFE approach even when performed by relatively inexperienced robotic surgeons.
Other potential strategies that advise a surgeon when to use a NS approach include reliance on preoperative imaging to evaluate if there is neurovascular involvement. Multiparametric MRI boasts high diagnostic accuracy for index lesions within the prostate. However, its ability to predict extracapsular extension and neurovascular involvement is poor. Rud et al. [17] in a randomised control trial compared PSM rates between patients who had an MRI before RALP and patients who had a RALP without an MRI. They concluded MRI before RALP did [18] . However, none of these have yet translated into widespread clinical practice.
The present study has a few limitations. This is a nonrandomised study and hence inherits with it biases associated with this approach. The more contemporary NeuroSAFE cohort introduces the element of chronology bias. Additionally, we did not use validated questionaries' to evaluate continence and erectile functional outcomes. However, the clinicians documenting patient follow-up did observe a stringent consistent recording policy, which was adopted by the operating surgeon. Although the PSM rates decreased significantly, our oncological follow-up data are not long enough to comment on the long-term safety of this approach. However, we can confidently say there is no increased rate of BCR in the short term. Furthermore, at the time of the present study, we did not offer patients RP if there was preoperative suspicion of clinical T3b disease on either clinical or radiological grounds, as it was our network policy at the time that these patients should be offered high-dose radiotherapy with brachytherapy boost. Additionally, the favourable reported results are those of a single experienced surgeon in our unit. In order to prove the benefits of rolling out the NeuroSAFE approach across all our robotic surgeons, we will wait for their data to mature and aim to address this question in a follow-up paper. Also, the specimens were evaluated by one histopathologist. Validation of these results by a second pathologist would have confirmed inter-observer reliability.
Future research will have to concentrate on cost analysis of the NeuroSAFE technique. In our institution, the cost difference of analysing a NeuroSAFE and a regular RALP specimen has been estimated to be £550. This includes the additional hour for a consultant pathologist, two technicians and consumables (20 extra slides) required to perform the frozen section. This would need to be weighed up against downstream long-term savings on treatments for erectile dysfunction, incontinence and further cancer treatments (if any). The true cost difference would need to be assessed as part of a randomised controlled trial. Prospective comparative studies between the NeuroSAFE technique and other clinical tools such as preoperative MRI, DRE, and biopsy results would be of interest as well. Longer term follow-up of patients undergoing this technique will help validate its oncological safety in terms of BCR.
Conclusion
The NeuroSAFE technique has allowed us to perform NS RALPs in a significantly greater proportion of patients with higher-risk prostate cancer, whilst at the same time significantly reducing the overall PSM rate and maintaining oncological safety. In addition, the NeuroSAFE approach significantly improved 12-month potency for bilateral and unilateral NS operations. Further study is needed to validate the approach across multiple surgeons and centres, and confirm its long-term oncological safety.
